Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have received an average rating of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $90.50.

A number of research firms have recently issued reports on TARS. Guggenheim cut their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating for the company in a report on Tuesday, July 21st. HC Wainwright reiterated a “buy” rating and issued a $88.00 price target on shares of Tarsus Pharmaceuticals in a research note on Thursday, July 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen cut shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Finally, Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a research note on Friday, April 24th. They set an “outperform” rating and a $98.00 target price on the stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, Director William J. Phd Link sold 12,500 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $62.12, for a total value of $776,500.00. Following the completion of the sale, the director directly owned 106,786 shares of the company’s stock, valued at $6,633,546.32. This trade represents a 10.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jeffrey S. Farrow sold 14,396 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $60.95, for a total value of $877,436.20. Following the transaction, the insider owned 56,801 shares of the company’s stock, valued at approximately $3,462,020.95. This represents a 20.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 39,850 shares of company stock valued at $2,452,821 over the last quarter. 9.64% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Tarsus Pharmaceuticals by 5.6% in the fourth quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock worth $196,476,000 after purchasing an additional 127,470 shares in the last quarter. TimesSquare Capital Management LLC raised its position in shares of Tarsus Pharmaceuticals by 24.3% during the 4th quarter. TimesSquare Capital Management LLC now owns 332,446 shares of the company’s stock valued at $27,221,000 after acquiring an additional 64,941 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Tarsus Pharmaceuticals by 19.9% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 109,857 shares of the company’s stock valued at $8,995,000 after purchasing an additional 18,267 shares during the last quarter. D.A. Davidson & CO. acquired a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $1,493,000. Finally, Ishara Investments LP bought a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth $1,965,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Stock Performance

NASDAQ:TARS opened at $58.66 on Wednesday. The business has a fifty day simple moving average of $61.54 and a two-hundred day simple moving average of $65.92. The company has a market capitalization of $2.52 billion, a P/E ratio of -51.46 and a beta of 0.50. Tarsus Pharmaceuticals has a 1 year low of $38.51 and a 1 year high of $85.25. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The firm had revenue of $162.05 million during the quarter, compared to analyst estimates of $149.60 million. On average, analysts expect that Tarsus Pharmaceuticals will post -1.04 earnings per share for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.